apecotrep

News

Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.

News

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.